Analyst: Diagnostics Sector R&D Spending Won't Match FDA Data Demands

The R&D spend to revenue ratio at emerging and established pure-play diagnostic companies is not sufficient to meet growing FDA requirements for the space, a Morgan Stanley analyst argues.